Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alexander Burnett

Concepts (195)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Laparoscopy
7
2024
170
2.120
Why?
Endometrial Neoplasms
8
2024
138
1.960
Why?
Uterine Cervical Neoplasms
12
2022
277
1.770
Why?
Lymph Node Excision
5
2024
134
1.580
Why?
Neoplasm Staging
8
2024
740
0.940
Why?
Obesity, Morbid
2
2023
78
0.930
Why?
Natural Orifice Endoscopic Surgery
1
2023
4
0.920
Why?
Gynecologic Surgical Procedures
4
2009
30
0.880
Why?
Whole-Body Irradiation
2
2014
131
0.880
Why?
Sentinel Lymph Node Biopsy
1
2024
116
0.880
Why?
Metformin
2
2020
64
0.660
Why?
Hypoglycemic Agents
2
2020
168
0.630
Why?
Interleukin-11
2
2013
5
0.540
Why?
Neoplasm Recurrence, Local
3
2016
614
0.500
Why?
2-Pyridinylmethylsulfinylbenzimidazoles
1
2014
19
0.480
Why?
Prescription Drugs
1
2014
38
0.470
Why?
Hysterectomy
4
2023
88
0.460
Why?
Uterine Neoplasms
7
2007
60
0.460
Why?
Proton Pump Inhibitors
1
2014
84
0.450
Why?
Radiation Tolerance
1
2014
85
0.450
Why?
Radiation-Protective Agents
1
2013
74
0.440
Why?
Obesity
2
2016
1113
0.430
Why?
Robotics
2
2010
43
0.420
Why?
Female
32
2024
26472
0.410
Why?
Organotechnetium Compounds
1
2011
6
0.390
Why?
Lymphedema
1
2011
43
0.370
Why?
Vulvar Neoplasms
1
2011
52
0.360
Why?
Lower Extremity
1
2011
88
0.360
Why?
Carcinoma, Squamous Cell
2
2011
318
0.350
Why?
Radiopharmaceuticals
1
2011
209
0.350
Why?
Cystadenocarcinoma, Papillary
5
2006
14
0.330
Why?
Humans
34
2024
49974
0.310
Why?
Adult
19
2024
13236
0.300
Why?
Fertility
2
2009
28
0.300
Why?
Aged
16
2024
9310
0.300
Why?
Retroperitoneal Space
2
2024
30
0.300
Why?
Retrospective Studies
5
2023
6108
0.300
Why?
Middle Aged
18
2024
12069
0.290
Why?
Vagina
2
2023
45
0.290
Why?
Cervix Uteri
1
2006
49
0.260
Why?
Adenocarcinoma
1
2009
396
0.260
Why?
Topotecan
1
2005
17
0.250
Why?
Polyethylene Glycols
1
2005
93
0.240
Why?
Postoperative Complications
1
2011
984
0.230
Why?
Genital Neoplasms, Female
1
2004
41
0.230
Why?
Ovarian Neoplasms
4
2014
447
0.220
Why?
Feasibility Studies
2
2024
375
0.220
Why?
Doxorubicin
1
2005
233
0.220
Why?
Uterus
1
2023
94
0.220
Why?
Lymph Nodes
1
2004
260
0.210
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2007
989
0.210
Why?
Gene Expression Regulation, Neoplastic
6
2011
828
0.210
Why?
Aged, 80 and over
5
2016
3129
0.190
Why?
Prospective Studies
3
2024
2364
0.180
Why?
Intestines
2
2013
176
0.170
Why?
Carcinoma
2
2011
138
0.150
Why?
Cell Proliferation
2
2020
1007
0.150
Why?
Cancer Vaccines
3
2014
78
0.150
Why?
Antineoplastic Agents
2
2007
1171
0.150
Why?
Dendritic Cells
3
2014
133
0.150
Why?
Kruppel-Like Transcription Factors
2
2020
36
0.140
Why?
Cystadenocarcinoma, Serous
3
2005
70
0.140
Why?
Enterotoxins
2
2007
12
0.140
Why?
Aromatase Inhibitors
2
2007
14
0.140
Why?
Pregnancy
1
2023
2607
0.130
Why?
Nitriles
2
2007
54
0.130
Why?
Kallikreins
2
2006
18
0.130
Why?
Mice
4
2014
5739
0.130
Why?
Triazoles
2
2007
108
0.130
Why?
Receptor, erbB-2
2
2005
73
0.130
Why?
Neoplasms
1
2005
1235
0.120
Why?
Medical Oncology
2
2006
94
0.120
Why?
Lethal Dose 50
1
2014
12
0.120
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
1
2014
16
0.120
Why?
Hematopoiesis
1
2014
71
0.120
Why?
Hydrogen-Ion Concentration
1
2014
175
0.120
Why?
Ascites
1
2014
28
0.120
Why?
Safety
1
2014
78
0.120
Why?
Survival Analysis
2
2013
653
0.110
Why?
Stomach
1
2014
80
0.110
Why?
Spectrometry, Fluorescence
1
2013
45
0.110
Why?
Carcinoma, Endometrioid
2
2010
38
0.110
Why?
Incidence
1
2016
1003
0.110
Why?
CD4-Positive T-Lymphocytes
1
2014
164
0.100
Why?
Administration, Oral
1
2013
426
0.100
Why?
Papillomaviridae
3
2013
102
0.100
Why?
Animals
5
2014
13187
0.100
Why?
Cytokines
1
2014
612
0.090
Why?
Arkansas
1
2016
1977
0.090
Why?
Cerclage, Cervical
1
2009
8
0.090
Why?
Treatment Outcome
3
2011
5141
0.090
Why?
Estrogens
1
2011
227
0.080
Why?
Gene Amplification
2
2005
57
0.080
Why?
Genes, erbB-2
2
2005
8
0.080
Why?
Male
4
2014
25241
0.080
Why?
Carcinoma, Papillary
2
2005
48
0.080
Why?
Membrane Proteins
2
2007
341
0.070
Why?
Intestinal Diseases
1
2007
25
0.070
Why?
Melanoma
1
2011
285
0.070
Why?
Leiomyosarcoma
1
2007
23
0.070
Why?
Clostridium perfringens
1
2007
6
0.070
Why?
Carcinosarcoma
1
2007
18
0.070
Why?
Radiation Injuries, Experimental
1
2007
81
0.070
Why?
Endometrium
2
2020
41
0.070
Why?
Infertility, Female
1
2006
18
0.070
Why?
Oncogene Proteins, Viral
1
2005
52
0.060
Why?
Fellowships and Scholarships
1
2006
111
0.060
Why?
Dysgerminoma
1
2004
3
0.060
Why?
Medroxyprogesterone Acetate
1
2004
6
0.060
Why?
Patient Selection
1
2006
253
0.060
Why?
Gynecology
1
2004
49
0.060
Why?
Immunotherapy, Adoptive
1
2005
156
0.060
Why?
Interleukin-6
1
2005
264
0.060
Why?
Lymphatic Metastasis
1
2004
224
0.060
Why?
Drug Therapy, Combination
1
2005
377
0.060
Why?
Antibodies, Monoclonal
1
2007
459
0.050
Why?
Adolescent
4
2013
6356
0.050
Why?
Immunohistochemistry
4
2007
973
0.050
Why?
Immunotherapy
1
2005
238
0.050
Why?
DNA-Binding Proteins
1
2005
427
0.050
Why?
Cells, Cultured
3
2014
1573
0.050
Why?
Education, Medical, Graduate
1
2004
205
0.050
Why?
Lung Neoplasms
1
2007
606
0.050
Why?
Preoperative Period
1
2020
46
0.040
Why?
Gene Expression Profiling
1
2005
1032
0.040
Why?
PTEN Phosphohydrolase
1
2020
55
0.040
Why?
Receptors, Progesterone
1
2020
63
0.040
Why?
Estrogen Receptor alpha
1
2020
89
0.040
Why?
Cell Line, Tumor
3
2007
1403
0.040
Why?
Pilot Projects
1
2020
699
0.040
Why?
Claudin-3
2
2007
5
0.030
Why?
Claudin-4
2
2007
7
0.030
Why?
Mice, SCID
2
2007
175
0.030
Why?
Lymphocyte Activation
2
2007
172
0.030
Why?
Enzyme-Linked Immunosorbent Assay
2
2006
244
0.030
Why?
In Situ Hybridization, Fluorescence
2
2005
259
0.030
Why?
Apoptosis
1
2020
1101
0.030
Why?
Coculture Techniques
1
2014
146
0.030
Why?
p38 Mitogen-Activated Protein Kinases
1
2014
96
0.030
Why?
Human Umbilical Vein Endothelial Cells
1
2014
90
0.030
Why?
Combined Modality Therapy
2
2007
637
0.030
Why?
Optics and Photonics
1
2013
12
0.030
Why?
Antigens, Neoplasm
1
2014
151
0.030
Why?
Drug Resistance, Neoplasm
2
2005
308
0.030
Why?
Spectrum Analysis
1
2013
70
0.030
Why?
Uterine Cervical Dysplasia
1
2013
49
0.030
Why?
RNA, Messenger
2
2005
1105
0.020
Why?
Early Detection of Cancer
1
2013
169
0.020
Why?
Papillomavirus Infections
1
2013
155
0.020
Why?
Gene Silencing
1
2011
119
0.020
Why?
Prognosis
2
2005
1942
0.020
Why?
Antibody-Dependent Cell Cytotoxicity
1
2007
12
0.020
Why?
Mast Cells
1
2007
52
0.020
Why?
Neoplasm Transplantation
1
2007
85
0.020
Why?
Antineoplastic Agents, Hormonal
1
2007
47
0.020
Why?
Remission Induction
1
2007
207
0.020
Why?
Transforming Growth Factor beta
1
2007
144
0.020
Why?
Lymphocytes
1
2007
152
0.020
Why?
Intestinal Mucosa
1
2007
225
0.020
Why?
Recombinant Proteins
1
2007
486
0.020
Why?
Hypersensitivity, Delayed
1
2005
21
0.020
Why?
Papillomavirus E7 Proteins
1
2005
31
0.020
Why?
Sampling Studies
1
2005
37
0.020
Why?
Antigens, Viral
1
2005
44
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
225
0.020
Why?
Probability
1
2005
164
0.020
Why?
Injections, Intraperitoneal
1
2005
54
0.020
Why?
Paraffin Embedding
1
2005
53
0.020
Why?
Statistics, Nonparametric
1
2005
194
0.020
Why?
Biopsy, Needle
1
2005
183
0.020
Why?
Carboplatin
1
2004
53
0.020
Why?
Etoposide
1
2004
72
0.020
Why?
Xenograft Model Antitumor Assays
1
2005
211
0.020
Why?
B-Lymphocytes
1
2005
170
0.020
Why?
Chemotherapy, Adjuvant
1
2004
119
0.020
Why?
Flow Cytometry
1
2007
476
0.020
Why?
Receptors, Cell Surface
1
2005
122
0.010
Why?
Tumor Cells, Cultured
1
2005
465
0.010
Why?
Polymerase Chain Reaction
1
2005
453
0.010
Why?
Proportional Hazards Models
1
2005
402
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2005
595
0.010
Why?
Rats, Sprague-Dawley
1
2007
1597
0.010
Why?
Young Adult
1
2013
3958
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2005
411
0.010
Why?
Clinical Competence
1
2006
393
0.010
Why?
T-Lymphocytes
1
2005
338
0.010
Why?
Sensitivity and Specificity
1
2005
861
0.010
Why?
Case-Control Studies
1
2006
1131
0.010
Why?
Survival Rate
1
2005
894
0.010
Why?
Disease-Free Survival
1
2003
454
0.010
Why?
Regression Analysis
1
2003
395
0.010
Why?
Age Factors
1
2005
1087
0.010
Why?
Rats
1
2007
3305
0.010
Why?
Risk Assessment
1
2005
1259
0.010
Why?
Child
1
2004
6847
0.010
Why?
Burnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description